Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 93-101, 2005; 10.1373/clinchem.2004.036236
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grau, M.
Right arrow Articles by Capellá, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grau, M.
Right arrow Articles by Capellá, G.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2005;51:93-101.)
© 2005 American Association for Clinical Chemistry, Inc.

Cancer Diagnostics

Validation of RNA Arbitrarily Primed PCR Probes Hybridized to Glass cDNA Microarrays: Application to the Analysis of Limited Samples

Mònica Grau1,1, Xavier Solé1,1, Antònia Obrador1, Gemma Tarafa1, Elisenda Vendrell2, Joan Valls1, Victor Moreno1, Miquel A. Peinado2 and Gabriel Capellá1,a

Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)-Institut Català d’Oncologia,1 Translational Research Laboratory, Unit of Biostatistics and Bioinformatics, Cancer Epidemiology Department, and 2 IDIBELL-Institut de Recerca Oncològica Molecular Oncology Center, L’Hospitalet de Llobregat, Barcelona, Spain.

aAddress correspondence to this author at: Institut Català d’Oncologia, Laboratori de Recerca Translacional, Av. Gran Via s/n, Km 2.7, 08907 L’Hospitalet de Llobregat, Barcelona, Spain. Fax 34-93-2607466; e-mail gcapella{at}ico.scs.es.

Background: The applicability of microarray-based transcriptome massive analysis is often limited by the need for large amounts of high-quality RNA. RNA arbitrarily primed PCR (RAP-PCR) is an unbiased fingerprinting PCR technique that reduces both the amount of initial material needed and the complexity of the transcriptome. The aim of this study was to evaluate the feasibility of using hybridization of RAP-PCR products as transcriptome representations to analyze differential gene expression in a microarray platform.

Methods: RAP-PCR products obtained from samples with limited availability of biological material, such as experimental metastases, were hybridized to conventional cDNA microarrays. We performed replicates of self-self hybridizations of RAP-PCR products and mathematical modeling to assess reproducibility and sources of variation.

Results: Gene/slide interaction (47.3%) and the PCR reaction (33.8%) accounted for the majority of the variability. From these observations, we designed a protocol using two pools of three independent RAP-PCR reactions coming from two independent reverse transcription reactions hybridized in duplicate and evaluated them in the analyses of paired xenograft-metastases samples. Using this approach, we found that HER2 and MMP7 may be down-regulated during distal dissemination of colorectal tumors.

Conclusion: RAP-PCR glass array hybridization can be used for transcriptome analysis of small samples.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.